Evaluation of Apremilast as a Potential Inhibitor of Activated Factor XII: In-Vitro and In-Silico Approaches

سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 104

فایل این مقاله در 16 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_AJCS-9-6_009

تاریخ نمایه سازی: 16 تیر 1405

چکیده مقاله:

This study aimed to evaluate the inhibitory effects of apremilast on activated coagulation factor XII (FXIIa) using chromogenic enzyme assays and to examine molecular interactions between apremilast and benzamidine with the target protein ۶I۶۳ (FXIIa) through in silico techniques including docking, structural analyses, and dynamic simulations. The interaction strength of these complexes, focusing on hydrogen bonds, Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), and Solvent Accessible Surface Area (SASA), was analyzed. Additionally, the selectivity of apremilast toward FXIIa over other related serine proteases (FIXa, FXa, FXIa, and plasma kallikrein) was determined using chromogenic assays. The findings indicated that apremilast has a significant inhibitory effect on FXIIa, while no notable effects were observed on the other proteases, suggesting selectivity for FXIIa. Furthermore, apremilast showed stronger binding affinity with ۶I۶۳ (−۶.۹ kcal/mol) compared to benzamidine (−۵.۳ kcal/mol), indicating a more stable and specific interaction. Apremilast induced greater compactness and stability of the complex, with lower RMSD and SASA values, whereas benzamidine favored a more flexible and less stable interaction. These results highlight distinct mechanisms by which each ligand interacts with FXIIa and provide insights into their therapeutic potential, suggesting apremilast could be effective in treating FXIIa-related diseases. In addition, ADME analysis revealed that benzamidine has better solubility, intestinal absorption, and excretion, while apremilast exhibits superior oral absorption and stronger inhibition of cytochrome P۴۵۰ enzymes. Toxicity studies showed both compounds are mutagenic. Taken together, apremilast could serve as a lead compound for developing new therapeutic agents targeting FXIIa-related diseases.

نویسندگان

Hassan A. Madkhali

Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia

Mohd Nazam Ansari

Department of Pharmacology & Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj ۱۱۹۴۲, Saudi Arabia

Yassine Riadi

Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, ۱۱۹۴۲ Al-Kharj, Saudi Arabia

Majid A. Ganaie

College of Dentistry and Pharmacy, Buraydah Colleges, Buraydah, Saudi Arabia

Abdullah Y. Hamadi

Faculty of Applied Medical Sciences, Medical Laboratory Technology, University of Tabuk, Tabuk, Saudi Arabia

Naif M. Alhawiti

King Abdullah International Medical Research Center, Ministry of National Guard for Health Affairs, Riyadh, Saudi Arabia

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Danese, E., Montagnana, M., Lippi, G. Factor XII in hemostasis ...
  • Reddigari, S.R., Shibayama, Y., Brunnée, T., Kaplan, A.P. Human Hageman ...
  • Gailani, D., Renné, T. Intrinsic pathway of coagulation and arterial ...
  • Schmaier, A.H., McCrae, K.R. The plasma kallikrein-kinin system: Its evolution ...
  • Dorgalaleh, A., Hosseini, M. S., Mobaraki, R. N., Alizadeh, S., ...
  • Reed, M., Crosbie, D. Apremilast in the treatment of psoriatic ...
  • Poole, R.M., Ballantyne, A.D. Apremilast: First global approval. Drugs, ۲۰۱۴, ...
  • Blair, H.A. Apremilast: First pediatric approval. Paediatric Drugs, ۲۰۲۴, ۲۷(۱), ...
  • Gelfand, J.M., Shin, D.B., Armstrong, A.W., Tyring, S.K., Blauvelt, A., ...
  • Cavanaugh, C., Orroth, K., Qian, X., Kumparatana, P., Klyachkin, Y., ...
  • Nassim, D., Alajmi, A., Jfri, A., Pehr, K. Apremilast in ...
  • Monteiro, F., Vittal Shetty, V., Acharaya, R., Naresh, S., Munikumar, ...
  • Manne, M. Multitargeted therapy in the convergence era: Systems pharmacology, ...
  • Madkhali, H., Tarawneh, A., Ali, Z., Le, H.V., Cutler, S.J., ...
  • Madkhali, H.A., Ansari, M.N., Alamri, M.A. Inhibition of activated coagulation ...
  • Trott, O., Olson, A.J. Autodock vina: Improving the speed and ...
  • Eberhardt, J., Santos-Martins, D., Tillack, A.F., Forli, S. Autodock vina ...
  • Ungarala, R., Munikumar, M., Sinha, S.N., Kumar, D., Sunder, R.S., ...
  • Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., ...
  • Ram, T.S., Munikumar, M., Raju, V.N., Devaraj, P., Boiroju, N.K., ...
  • Naik, V.R., Munikumar, M., Ramakrishna, U., Srujana, M., Goudar, G., ...
  • Lu, S.H., Wu, J.W., Liu, H.L., Zhao, J.H., Liu, K.T., ...
  • Schrödinger, L., DeLano, W., PyMOL. ۲۰۲۰, Retrieved from http://www.pymol.org/pymol[۲۴] Manne, ...
  • Abraham, M.J., Murtola, T., Schulz, R., Páll, S., Smith, J.C., ...
  • Pamu, D., Ayyamperumal, S., Manne, M., Tallapaneni, V., Moola, C.J.N., ...
  • Zoete, V., Cuendet, M.A., Grosdidier, A., Michielin, O. Swissparam: A ...
  • Ke, Q., Gong, X., Liao, S., Duan, C., Li, L. ...
  • DeLa Cadena, R., Laskin, K.J., Pixley, R.A., Sartor, R.B., Schwab, ...
  • Kolte, D., Shariat-Madar, Z. Plasma kallikrein inhibitors in cardiovascular disease: ...
  • Varikasuvu, S.R., Thangappazham, B., Vykunta, A., Duggina, P., Manne, M., ...
  • Knapp, B., Frantal, S., Cibena, M., Schreiner, W., Bauer, P. ...
  • Krebs, B.B., De Mesquita, J.F. Amyotrophic lateral sclerosis type ۲۰-in ...
  • Challa, B.R., Kantamneni, G.D., Suravajhala, M., Vadlamudi, S., Manne, M., ...
  • نمایش کامل مراجع